Latest news


Extension of preclinical research collaboration agreement with a top-10 large pharma company

Posted on Dec 18, 2018

Oslo (Norway), 18 December 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over 6 months, until the end of June 2019, and may be further extended. The […]

Third quarter 2018 results

Posted on Nov 13, 2018

Oslo (Norway), 13 November 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its interim third quarter 2018 result. Please find enclosed the report and presentation. The fully underwritten rights issue of NOK 360 million completed in October 2018 provides PCI Biotech with the funds needed for the pivotal fimaCHEM study, […]

Invitation to third quarter 2018 presentation

Posted on Nov 6, 2018

Oslo, Norway, 06 November 2018 – PCI Biotech invites to a presentation of the company’s third quarter 2018 report on Tuesday 13 November 2018 at Oslo Cancer Cluster Innovation Park. Time: Tuesday November 13, 08:30am – 09:30am CET (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, […]